Gilead Sciences Non-GAAP EPS of $1.34 misses by $0.30, revenue of $6.59B beats by $140M
Gilead Sciences press release (NASDAQ:GILD): Q2 Non-GAAP EPS of $1.34  misses by $0.30.
Revenue of $6.59B (+5.3% Y/Y)  beats by $140M.

For the full-year, Gilead expects:

Total product sales between $26.3 billion and $26.7 billion, compared to $26.0 billion and $26.5 billion previously.
Total product sales, excluding Veklury, between $24.6 billion and $25.0 billion, compared to $24.0 billion and $24.5 billion previously.
Total Veklury sales of approximately $1.7 billion, compared to approximately $2.0 billion previously.
Diluted earnings per share between $4.50 and $4.85, compared to $4.75 and $5.15 previously.
Non-GAAP diluted earnings per share between $6.45 and $6.80 vs $6.73 consensus, compared to $6.60 and $7.00 previously.